T7455
Tolvaptan
≥98% (HPLC), powder
동의어(들):
N-[4-[(7-Chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methylbenzamide, OPC 41061
로그인조직 및 계약 가격 보기
모든 사진(2)
About This Item
실험식(Hill 표기법):
C26H25ClN2O3
CAS Number:
Molecular Weight:
448.94
MDL number:
UNSPSC 코드:
51111800
PubChem Substance ID:
NACRES:
NA.77
추천 제품
![[deamino-Cys1, D-Arg8]-Vasopressin acetate salt hydrate ≥95% (HPLC)](/deepweb/assets/sigmaaldrich/product/structures/215/222/82da3633-80ea-463d-8b55-e99fb8e442e0/640/82da3633-80ea-463d-8b55-e99fb8e442e0.png)
![[Arg8]-Vasopressin acetate salt ≥95% (HPLC)](/deepweb/assets/sigmaaldrich/product/structures/282/717/a4c16d4f-e168-4d84-a0e3-59de3e06251e/640/a4c16d4f-e168-4d84-a0e3-59de3e06251e.png)
Quality Level
분석
≥98% (HPLC)
양식
powder
색상
white to tan
solubility
DMSO: ≥15 mg/mL
주관자
Sanofi Aventis
저장 온도
2-8°C
SMILES string
Cc1ccccc1C(=O)Nc2ccc(c(C)c2)C(=O)N3CCCC(O)c4cc(Cl)ccc34
InChI
1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31)
InChI key
GYHCTFXIZSNGJT-UHFFFAOYSA-N
유전자 정보
human ... AVPR2(554)
애플리케이션
Tolvaptan has been used as a V2-selective antagonist for studying its effect on hypertension in mice.
생화학적/생리학적 작용
Tolvaptan (OPC 41061) is a potent, orally active non-peptide vasopressin V2 selective antagonist. IC50 = 3 nM at the rat V2 receptor; 29 times more selective for the V2 than for V1a. Tolvaptan has also been shown to inhibit the development of polycystic kidney disease in several animal models.
Tolvaptan is a potent, orally active non-peptide vasopressin V2 receptor antagonist.
특징 및 장점
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
제조 메모
Tolvaptan is soluble in DMSO at a concentration that is greater than or equal to 15 mg/ml.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
이미 열람한 고객
Vicente E Torres et al.
The New England journal of medicine, 367(25), 2407-2418 (2012-11-06)
The course of autosomal dominant polycystic kidney disease (ADPKD) is often associated with pain, hypertension, and kidney failure. Preclinical studies indicated that vasopressin V(2)-receptor antagonists inhibit cyst growth and slow the decline of kidney function. In this phase 3, multicenter
Hyponatremia and outcomes in patients with heart failure.
Steven R Goldsmith
Heart (British Cardiac Society), 98(24), 1761-1762 (2012-12-04)
[Vasopressin antagonist in hyponatremia. Rapid and simple control of serum sodium concentration].
MMW Fortschritte der Medizin, 154(22), 78-79 (2013-01-10)
Nicole K Littlejohn et al.
American journal of physiology. Regulatory, integrative and comparative physiology, 304(10), R818-R828 (2013-03-29)
An indispensable role for the brain renin-angiotensin system (RAS) has been documented in most experimental animal models of hypertension. To identify the specific efferent pathway activated by the brain RAS that mediates hypertension, we examined the hypothesis that elevated arginine
Urine osmolality-guided tolvaptan therapy in decompensated heart failure.
Kaoru Dohi et al.
Circulation journal : official journal of the Japanese Circulation Society, 77(2), 313-314 (2012-12-28)
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.